Malay premature infants with retinopathy of prematurity: risk factors and screening of NDP gene mutation

Embong Zunaina, Ismail Abdul-Salim, Mohd-Khair Siti-Zulaikha-Nashwa, Abdul-Aziz Mohamed-Yusoff, Noraida Ramli, Mohd-Ismail Ibrahim, Ismail Shatriah

Abstract


The aim of this study is to determine the risk factors for retinopathy of prematurity (ROP), and also to screen Norrie Disease Pseudoglioma (NDP) gene mutation in order to determine if mutation in the NDP gene may play a role in the development of ROP among Malay premature infants. This was a case control study among Malay premature infants from Hospital Universiti Sains Malaysia (USM) conducted from August 2011 to May 2013. Written consent were taken from their parents before conducting the study. The stage of ROP, systemic risk factors (gestational age and birth weight) and enviromental risk factors (oxygen exposure and duration of ventilation) were reviewed from patients’ medical records. DNA was extracted from venous blood and subjected to polymerase chain reaction (PCR) before direct sequencing of NDP gene. A total of 56 Malay premature infants (Case group = 28 ROP premature infants, Control group = 28 non-ROP premature infants) from Hospital USM were enrolled in this study. Out of 28 premature infants with ROP, 11 (39.3%) premature infants were in stage 3. Only 1 (3.6%) premature infant in stage 4 and 2 (7.2%) premature infants in stage 5. The gestational age (p = 0.010) and birth weight (p = 0.010) were the significant risk factors for ROP. There was no significant difference of environmental risk factors between the two groups. The NDP gene mutation was not detected in Malay premature infants with ROP and also in control group. The gestational age and birth weight were important risk factors of ROP. Although NDP gene mutations were being linked to ROP but NDP gene mutation was not detected in premature infants with ROP as well as premature infants with non-ROP among Malay ethnic background.

Keywords


Low birth weight, Malay, Mutations, NDP gene, Prematurity, Retinopathy of prematurity

Full Text:

PDF

References


Sylvester CL. Retinopathy of prematurity. Semin Ophthalmol. 2008; 23:pp.318-323.

Gibson DL, Sheps SB, Uh SH, Schechter MT, McCormick AQ. Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics. 1990; 86(3):pp.405-412.

Hutcheson KA, Paluru PC, Bernstein SL, Koh J, Rappaport EF, et al. Norrie disease gene sequence variants in an ethnically diverse population with retinopathy of prematurity. Mol Vis. 2005; 11:pp.501-508.

Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia. A clinical approach. Med J Aust. 1951; 2(2):pp.48-50.

Lau YY, Tay YY, Shah VA, Chang P, Loh KT. Maintaining optimal oxygen saturation in premature infants. Prem J. 2011; 15(1):pp.108-113.

Vanderveen DK, Mansfield TA, Eichenwald EC. Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. J AAPOS. 2006; 10(5):pp.445-448.

Yang CS, Chen SJ, Lee FL, Hsu WM, Liu JH. Retinopathy of prematurity: screening, incidence and risk factors analysis. Zhonghua Yi Xue Za Zhi (Taipei). 2001; 64(12):pp.706-712.

Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, et al. Vascular development in the retina and inner ear: Control by norrin and frizzled-4, a high-affinity ligand-receptor pair. Cell. 2004; 116(6):pp.883-895.

Berger W. Molecular dissection of Norrie disease. Acta Anat (Basel). 1998; 162(2-3):pp.95-100.

Hiraoka M, Takahashi H, Orimo H, Hiraoka M, Ogata T, et al. Genetic screening of Wnt signaling factors in advanced retinopathy of prematurity. Mol Vis. 2010; 16:pp.2572-2577.

Dickinson JL, Sale MM, Passmore A, FitzGerald LM, Wheatley CM, et al. Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clin Exp Ophthalmol. 2006; 34(7):pp. 682-688.

Shastry BS, Pendergast SD, Hartzer MK, Liu X, Trese MT. Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. Arch Ophthalmol. 1997; 115:pp.651-655.

Ghaseminejad A, Hiknafs P. Distribution of retinopathy of prematurity and its risk factors. Iran J Pediatr. 2010; 21(2):pp.209-214.

Shah VA, Yeo CL, Ling YL, Ho LY. Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore. Ann Acad Med Singapore. 2005; 34(2):pp.169-178.

Tin W, Milligan DW, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed. 2001; 84(2):F106-F110.

Seiberth V, Linderkamp O. Risk factors in retinopathy of prematurity. A multivariate statistical analysis. Ophthalmologica. 2000; 214(2):pp.131-135.

Bizzaro MJ, Hussain N, Jonsson B, Feng R, Ment LR, et al. Genetic susceptibility to retinopathy of prematurity. Pediatrics. 2006; 118:pp.1858-1863.

Drenser KA, Dailey W, Vinekar A, Dalal K, Capone A Jr, et al. Clinical presentation and genetic correlation of patients with mutations affecting the FZD4 gene. Arch Ophthalmol. 2009; 127(12):pp.1649-1654.

Hatin WI, Nur-Shafawati AR, Zahri MK, Xu S, Jin L, et al. HUGO pan Asian SNP Consortium. Population genetic structure of peninsular Malaysia Malay sub-ethnic groups. PLoS ONE. 2011; 6(4):e18312.

Kim JH, Yu YS, Kim J, Park SS. Mutation of the Norrie gene in Korean ROP infants. Korean J Ophthalmol. 2002; 16(2):pp.93-96.

Haider MZ, Devarajan LV, Al-Essa M, Srivastva BS, Kumar H, et al. Missense mutations in Norrie disease gene are not associated with advanced stages of retinopathy of prematurity in Kuwaiti Arabs. Biol Neonat. 2000; 77(2):pp.88-91.




Copyright (c) 2017 Journal of Biomedical and Clinical Sciences (JBCS) (eISSN2550-147X)



 

Flag Counter           

                     

                                              Copyright © 2016 AMDI Publisher, Universiti Sains Malaysia.
Disclaimer : This website has been updated to the best of our knowledge to be accurate. However, Universiti Sains Malaysia shall not be liable for any loss or damage caused by the usage of any information obtained from this web site.
                                            Best viewed: Mozilla Firefox 4.0 & Google Chrome at 1024 × 768 resolution.